第二线粒体衍生的半胱天冬酶激活剂在宫颈鳞癌中的表达及其临床意义  

Expression of second mitochondria derived activator of caspase in cervical squamous carcinoma and its clinical significance

作　　者：彭彩霞[1] 黄丽辉[1] 杨毓琴[1] 闫春梅[1] 

机构地区：[1]甘肃省人民医院妇产科,甘肃兰州730000

出　　处：《兰州大学学报（医学版）》2010年第2期48-51,共4页Journal of Lanzhou University（Medical Sciences）

摘　　要：目的检测第二线粒体衍生的半胱天冬酶激活剂(Smac)蛋白在宫颈鳞癌组织中的表达,探讨其与临床病理因素及预后的关系。方法采用免疫组化方法检测Smac蛋白在175例宫颈鳞癌组织和49例正常宫颈组织中的表达情况。结果Ⅰ、Ⅱ和Ⅲ期宫颈鳞癌患者的5年生存率分别为68.9%、56.4%和36.5%。Smac蛋白主要定位于癌细胞浆,在正常宫颈组织中不表达。在175例宫颈鳞癌组织中87例表达阳性。临床分期Ⅰ、Ⅱ和Ⅲ期宫颈癌的阳性率分别为70.2%、47.2%和35.7%,其差异均具有统计学意义(P<0.01)。Smac蛋白在有淋巴结转移和无淋巴结转移的表达分别为23.8%和57.9%,二者比较差异具有统计学意义(P<0.01)。结论 Smac蛋白在宫颈鳞癌组织中表达下调,预示肿瘤有较高的侵袭性和患者预后不良。Objective To investigate the expression of second mitochondrial activator of caspase （Smac） in cervical squamous carcinoma and explore its correlations with clinicopathologic features and prognosis. Methods The expressions of Smac in 175 cervical squamous carcinoma tissues and 49 normal cervical tissues were detected by means of immunohistochemistry and its correlations with clinicopathologic features and prognosis in cervical squamous carcinoma were analyzed. Results The 5-year survival rates of the patients with stage Ⅰ, stage Ⅱ and stageⅢ in cervical squamous carcinoma were 68.9%, 56.4% and 36.5% respectively. Smac protein was mainly localized in cytoplasm and was expressed in 87 of 175 （49.7%） cases of cervical squamous carcinomas. However, it was not expressed in normal cervical tissues. The positive expression rates of Smac protein were 70.2%, 47.2% and 35.7% in clinical stage Ⅰ , stage Ⅱand stage Ⅲin cervical squamous carcinoma respectively （P 〈0.01）, and the positive rate of Smac protein was significantly lower in the patients with lymph node metastasis than that in the patients without lymph node metastasis （23.8% vs 57.9%, P 〈0.01）. Conclusion The down-regulation of the expression of Smac protein in cervical squamous carcinoma indicates that tumor has high invasion and the patients have unfavorable prognosis.

关 键 词：第二线粒体衍生的半胱天冬酶激活剂 宫颈癌 蛋白表达 

分 类 号：R737.33[医药卫生—肿瘤]